...
首页> 外文期刊>Expert opinion on therapeutic targets >The role of cellular flice inhibitory protein (c-FLIP) in the pathogenesis and treatment of cancer.
【24h】

The role of cellular flice inhibitory protein (c-FLIP) in the pathogenesis and treatment of cancer.

机译:细胞碎片抑制蛋白(c-FLIP)在癌症的发病机理和治疗中的作用。

获取原文
获取原文并翻译 | 示例
           

摘要

Protection from death receptor (DR)-mediated apoptosis has been proposed as an important step in the development of malignancy, enabling tumour cells not only to survive and escape antitumour immune responses, but also to develop resistance to chemotherapy or other cancer treatments. An important regulator of DR-induced death is the cellular FADD-like IL-1beta-converting enzyme inhibitory protein (c-FLIP) which, when overexpressed, can protect tumour cells from apoptosis. This review focuses on the role of c-FLIP as a tumour progression factor, with particular emphasis on recent work from the authors' laboratory concerning the contribution of c-FLIP to the pathogenesis of Hodgkin's lymphoma. The possibility of targeting c-FLIP as an approach to the treatment of cancer and, in particular, Hodgkin's lymphoma is discussed.
机译:有人提出保护免受死亡受体(DR)介导的细胞凋亡是恶性肿瘤发展的重要步骤,使肿瘤细胞不仅能够生存并逃脱抗肿瘤免疫反应,而且还可以发展出对化学疗法或其他癌症治疗的抵抗力。 DR诱导的死亡的重要调节剂是细胞FADD样IL-1beta转换酶抑制蛋白(c-FLIP),当其过表达时,可以保护肿瘤细胞免于凋亡。这篇综述着重于c-FLIP作为肿瘤进展因子的作用,特别着重作者实验室关于c-FLIP对霍奇金淋巴瘤发病机理的贡献的最新研究。讨论了靶向c-FLIP作为治疗癌症,特别是霍奇金淋巴瘤的方法的可能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号